Caplin Point Laboratories Limited

Caplin Point Laboratories demonstrated exceptional financial performance in FY26, with revenue doubling from INR 1,085 crores to INR 2,300 crores. The company's liquid assets tripled to INR 2,726 crores, and free cash reserves also tripled to INR 1,471 crores. This robust cash generation contributed to a 26% expansion in net worth, reaching INR 3,331 crores, and an operating cash flow exceeding INR 500 crores, all while maintaining a virtually debt-free status.

The company is heavily investing in future growth, with INR 900 crores in capex over the last five years and an additional INR 510 crores planned for the next 18-24 months. These investments are directed towards building new injectable factories, aiming for 17 lines for US and regulated markets, a derma facility, an oncology API plant, and a factory in Mexico. Caplin Point is also digitalizing its factories with Video Master and Visual SOPs, which are expected to enhance operational efficiency and quality control.

Caplin Point's US business is transitioning from foundation building to scaling, with its own label operations generating nearly INR 100 crores in revenue in its first full year. The company successfully secured 60 ANDA approvals to date, including 10 in the last four quarters and 15 acquired ANDAs. Management aims to double its US own label revenue in FY27 and expects the overall Caplin Steriles (CSL) business to grow by 25-30% next year, with CSL's FY26 EBITDA at 30% (INR 142 crores).

In Latin America, Caplin Point is expanding its footprint, particularly in Chile, where it has 135 products registered and expects $10 million in supplies over the next 18 months. In Mexico, the company anticipates $4 million in sales in the coming two quarters and has acquired land for a new factory. The strategy involves strengthening shelf space in independent pharmacies (currently 41%, targeting 50-55%) and potentially acquiring distribution companies to enhance market reach. A large tender in Salvador contributed INR 50-55 crores to Q4 revenue, temporarily increasing receivables.

While receivables grew ahead of revenue, reaching 125 days (excluding FCTR impact), this was attributed to the timing of^📎 a large tender in Salvador, with collections expected by Q2 FY27. Management emphasized its 'anti-fragile' business model, which involves maintaining six-month stock in subsidiary warehouses, allowing them to manage raw material price volatility and currency swings. They also noted that price increases are passed on, and the impact of global tensions on their business is minimal due to their unique model and market focus.